Peptide Knowledge Base · GH-axis
CJC-1295: what it is, what the evidence says, and its real status
A growth-hormone-releasing peptide usually stacked with Ipamorelin, but non-compoundable in the US.
Short version: a popular GH-axis peptide the FDA placed in compounding Category 2 in 2023, non-compoundable. We can educate, never sell. The legal GH-axis route is Sermorelin.
Can you actually get it?
Plain-English verdict: Education only.
Regulatory status: FDA Category 2 (non-compoundable) · Education only.
Not available, and not on a path to be. CJC-1295 has been on FDA compounding Category 2 since September 2023, it cannot be legally compounded. We never list it as available; the legal GH-axis answer is Sermorelin.
How does CJC-1295 work?
A long-acting GHRH analog that stimulates pituitary growth-hormone release, often combined with a GH secretagogue like Ipamorelin.
What it does — and what it does not do
What it does: Studied as a GH-axis stimulator for recovery and body-composition interest.
What it does not do: It cannot be legally compounded in the US, and Peptós.LIFE does not offer it, it is education only.
How honest is the evidence?
Evidence grade C — modest human GHRH-analog data; long-acting (DAC) variants less characterized. Read our grading methodology for what each grade means.
What we still don't know: Long-term safety of the long-acting (DAC) form is poorly characterized in humans.
WADA status: Banned (S2).
How it is taken
Not offered; education only.
Who should not take it
Banned in tested sport (WADA S2); not compoundable in the US. Not a substitute for evaluated GH-axis care.
Sources
GHRH-analog clinical literature · FDA compounding Category 2 list (Sept 2023)
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.